Contents

Search

lixisenatide (Adlyxin, Lyxumia)

Indications: - diabetes mellitus type 2 - may slow progression of Parkinson's disease [3] - lixisenatide therapy resulted in less progression of motor disability than placebo at 12 months (phase 2 trial) [3] * in patients with type 2 diabetes & recent acute coronary syndrome, lixisenatide did not significantly affect risk of major cardiovascular events [2] Dosage: - start 10 ug QD for 14 days, then increase to 20 ug QD disposable prefilled syringes Adverse effects: - hypoglycemia - gastrointestinal: nausea (46%)/vomiting (13%) - hypersensitivity reactions, including anaphyaxis [1] Mechanism of action: - glucagonlike-receptor (GLP-1) agonist

Interactions

drug adverse effects of hypoglycemic agents

General

glucagon-like peptide 1 (GLP-1) receptor agonist; incretin mimetic; GLP-1 mimetic; GLP-1 agonist; glutide; GLP-1RA

Database Correlations

PUBCHEM correlations

References

  1. GLP-1 Agonist Lixisenatide (Adlyxin) Okayed for Type 2 Diabetes in US. Medscape. Jul 28, 2016. http://www.medscape.com/viewarticle/866766 - FDA News Release. Jul 28, 2016 FDA approves Adlyxin to treat type 2 diabetes http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm513602.htm
  2. Pfeffer MA, Claggett B, Diaz R et al for the ELIXA Investigators. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015 Dec 3;373(23):2247-57. PMID: 26630143
  3. Adam D Diabetes drug slows development of Parkinson's disease. Nature News. April 3, 2024 https://www.nature.com/articles/d41586-024-00974-0 - Meissner WG et al Trial of Lixisenatide in Early Parkinson's Disease. N Engl J Med 2024;390:1176-1185 PMID: 38598572 https://www.nejm.org/doi/full/10.1056/NEJMoa2312323

Component-of

glargine/lixisenatide